TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31072359

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen (PPF) dissemination devices (0.2-0.3 g PPF in clay pots)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated chamber)
Number of subjects: 20
Study: 28122690

Group type: EXPERIMENTAL
Intervention: BATHE interview technique
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 112
Study: 26885511

Group type: EXPERIMENTAL
Intervention: Toyra(®) virtual reality system combined with conventional therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Toyra(®) virtual reality system
Number of subjects: 31
Study: 23001079

Group type: EXPERIMENTAL
Intervention: Stimulation at sensory threshold (ST)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Stimulation at 75% of the ST
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Stimulation at 50% of the ST
Number of subjects: 19
Study: 21095620

Group type: EXPERIMENTAL
Intervention: G-CSF (10 μg/kg s.c. for 5 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 18636325

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based intervention for HIV risk
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based intervention for HIV and IPV risk
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 530
Study: 17006874

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 101
Study: 15011930

Group type: COMPARATOR
Intervention: Mail group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Interactive group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study: 11709596

Group type: EXPERIMENTAL
Intervention: Hydrophilic primer
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional primer
Number of subjects: 33
Study: 8804929

Group type: EXPERIMENTAL
Intervention: Inhaled lysine-acetylsalicylate (L-ASA) 90 mg.mL-1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched placebo (glycine, 30 mg.mL-1)
Number of subjects: 9
Study: 1505562

Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ajmaline (50 mg)
Number of subjects: 61
Study: 6368960

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) subcutaneous on day 14
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) intravenous on day 14
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) subcutaneous on day 1
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) intravenous on day 1
Number of subjects: 222

Group type: COMPARATOR
Intervention: VAC/FMC chemotherapy
Number of subjects: 222
Study: 30698045

Group type: EXPERIMENTAL
Intervention: GP2017 (40 mg subcutaneous injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GP2017 via autoinjector (AI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GP2017 (AI and PFS)
Number of subjects: 0
Study: 29752620

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Body Image and Self-Care (CBT-BISC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 44
Study: 25689042

Group type: EXPERIMENTAL
Intervention: Malabsorption blood test (MBT) with pancreatic enzyme administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malabsorption blood test (MBT) without pancreatic enzyme administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Malabsorption blood test (MBT) with enzymes taken 30 minutes after MBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Malabsorption blood test (MBT) with enzymes taken 60 minutes after MBT
Number of subjects: 0
Study: 23535332

Group type: EXPERIMENTAL
Intervention: RESMENA diet (30% proteins, 30% lipids, 40% carbohydrates, seven-times/day, low glycemic load, high antioxidant capacity, high n-3 fatty acids)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control diet based on American Health Association criteria
Number of subjects: 79
Study: 22483680

Group type: EXPERIMENTAL
Intervention: Nabiximols (low dose: 1-4 sprays/day)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Nabiximols (medium dose: 6-10 sprays/day)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Nabiximols (high dose: 11-16 sprays/day)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 19103443

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 12
Study: 17227784

Group type: EXPERIMENTAL
Intervention: Stress echocardiography (SEcho)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Exercise electrocardiography (ExECG)
Number of subjects: 433
Study: 15191866

Group type: EXPERIMENTAL
Intervention: Jejunal interposition without a pouch (J-I)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Jejunal interposition with a pouch (J-P)
Number of subjects: 26
Study: 11682411

Group type: EXPERIMENTAL
Intervention: 500 mL mouth-to-mouth ventilation tidal volume
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1000 mL mouth-to-mouth ventilation tidal volume
Number of subjects: 20

Group type: COMPARATOR
Intervention: Room air control (21% oxygen)
Number of subjects: 20
Study: 10410576

Group type: EXPERIMENTAL
Intervention: A60-ELISA test with Immune kit
Number of subjects: 213

Group type: COMPARATOR
Intervention: Tuberculin test using 2 units of tuberculin Rt23
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: A60-ELISA test
Number of subjects: 213
Study: 9297313

Group type: EXPERIMENTAL
Intervention: Leucocyte‐filtrated blood
Number of subjects: 60

Group type: COMPARATOR
Intervention: Whole blood transfusion
Number of subjects: 60
Study: 2566112

Group type: EXPERIMENTAL
Intervention: Acebutolol 600 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Carteolol 20 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 269633

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 46

Group type: COMPARATOR
Intervention: No oxytocin infusion (Control)
Number of subjects: 46
Study: 31488492

Group type: EXPERIMENTAL
Intervention: 5 mg zoledronic acid (ZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28817434

Group type: EXPERIMENTAL
Intervention: Everolimus + reduced Tacrolimus (EVR + TAC)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Tacrolimus control (TAC)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Tacrolimus elimination (TAC elimination)
Number of subjects: 719
Study: 26297361

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 24144899

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) plus 2 NRTIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) plus EFV without NRTI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NRTI selection (ZDV, d4T, TDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPV/r
Number of subjects: 0

Group type: COMPARATOR
Intervention: EFV regimens without TDF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study: 21594217

Group type: EXPERIMENTAL
Intervention: Group A (2 g amoxicillin single preoperative dose)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group B (single preoperative 2 g amoxicillin followed by 500 mg three times daily for 5 days)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group C (postoperative amoxicillin with clavulanic acid 625 mg three times daily for 5 days)
Number of subjects: 240
Study: 19786634

Group type: EXPERIMENTAL
Intervention: TAXUS SR (n=131)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: TAXUS MR (n=135)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control (bare-metal stent, n=270)
Number of subjects: 536
Study: 16459722

Group type: EXPERIMENTAL
Intervention: 250 microg every other day (EOD) interferon beta-1b
Number of subjects: 149

Group type: COMPARATOR
Intervention: 30 microg once weekly (OW) interferon beta-1a
Number of subjects: 149
Study: 15684776

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Converted to open procedure (COC)
Number of subjects: 49
Study: 11526364

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 9241002

Group type: EXPERIMENTAL
Intervention: Moclobemide 900 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8512713

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2447516

Group type: EXPERIMENTAL
Intervention: Hemophane (HE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cuprophane (CU)
Number of subjects: 10
Study: 31620974

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention (n = 12 calls)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group receiving a single written recommendation
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 288
Study: 29105489

Group type: EXPERIMENTAL
Intervention: Short-term CHS (5 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Short-term CHS + vitamin C (12 g/100 l drinking water)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Medium-term CHS (10 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Medium-term CHS + vitamin C
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Long-term CHS (20 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Long-term CHS + vitamin C
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 26449267

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) for 3 weeks
Number of subjects: 0
Study: 25784660

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid t-16:1n9
Number of subjects: 4210

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid t-18:1
Number of subjects: 4210

Group type: EXPERIMENTAL
Intervention: Total dietary trans fatty acids (TFAs)
Number of subjects: 4210

Group type: EXPERIMENTAL
Intervention: Dietary t-18:1
Number of subjects: 4210

Group type: EXPERIMENTAL
Intervention: Dietary t-18:2
Number of subjects: 4210

Group type: EXPERIMENTAL
Intervention: Estimated dietary TFA after adjustment for other dietary habits
Number of subjects: 4210
Study: 23299256

Group type: EXPERIMENTAL
Intervention: Angular perturbations (3 and 6 degrees) in the coronal plane
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Angular perturbations in the sagittal plane
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Translational perturbations (5 and 10 mm) in the sagittal plane
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Coronal angle malalignments
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Other alignment conditions
Number of subjects: 11
Study: 20150450

Group type: EXPERIMENTAL
Intervention: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 2880 mg/d for days 0-14, 2160 mg/d for days 15-42, followed by 1440 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS) - 1440 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intensified dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard dosing of enteric‐coated mycophenolate sodium (EC‐MPS)
Number of subjects: 75
Study: 18321838

Group type: EXPERIMENTAL
Intervention: Nurse-led storytelling intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 15809365

Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sedentary lifestyle (Control)
Number of subjects: 23
Study: 12464832

Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention to enhance communication; Women in the intervention group used information and decision preference profiles generated by the computer program at their clinic appointments.
Number of subjects: 749

Group type: COMPARATOR
Intervention: Control group completed measures of decision preference before their clinic appointments.
Number of subjects: 749
Study: 10707452

Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 5
Study: 7571796

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle training with high motion velocities (150 degrees/s, motion limit 0‐20‐90 degrees)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Common physiotherapy only
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle training with high motion velocities
Number of subjects: 17
Study: 1683250

Group type: EXPERIMENTAL
Intervention: Abanoquil (0.5 micrograms kg‐1, intravenous bolus)
Number of subjects: 0
Study: 7228474

Group type: EXPERIMENTAL
Intervention: Elsinore pills (ephedrine and caffeine)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Diethylpropion
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 31533377

Group type: EXPERIMENTAL
Intervention: Functional exercise and partly weight‐bearing walking starting two days after operation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group immobilized with plaster in plantar flexion for two weeks before starting functional exercise
Number of subjects: 64
Study: 29355100

Group type: EXPERIMENTAL
Intervention: Disease salience
Number of subjects: 0
Study: 26510727

Group type: EXPERIMENTAL
Intervention: PanAd3-RSV and MVA-RSV vaccines (various combinations)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single dose of IM MVA-RSV
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IN or IM PanAd3-RSV prime and PanAd3-RSV or MVA-RSV boost vaccination
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laboratory measures of RSV-specific humoral and cellular immune responses
Number of subjects: 70
Study: 23645476

Group type: EXPERIMENTAL
Intervention: Eight-variable model (including age, sex, estimated glomerular filtration rate (eGFR), albuminuria, calcium, phosphate, bicarbonate, albumin)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Four-variable model (including age, sex, eGFR, albuminuria)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Three-variable model (including age, sex, eGFR)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Eight-variable model
Number of subjects: 595
Study: 22204725

Group type: EXPERIMENTAL
Intervention: Standard therapy plus bevacizumab (7.5 mg/kg), given every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease.
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Standard therapy (carboplatin and paclitaxel), given every 3 weeks for 6 cycles.
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Standard therapy plus bevacizumab (7.5 mg/kg).
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Standard therapy (carboplatin and paclitaxel).
Number of subjects: 1528
Study: 18603290

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical and thermal cycling of fiber reinforced composite specimens
Number of subjects: 0
Study: 17202550

Group type: EXPERIMENTAL
Intervention: Integrated group therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Group drug counseling
Number of subjects: 62
Study: 15771038

Group type: EXPERIMENTAL
Intervention: levofloxacin + ursodeoxycholic acid
Number of subjects: 90

Group type: COMPARATOR
Intervention: ursodeoxycholic acid alone
Number of subjects: 90
Study: 12068338

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9627865

Group type: EXPERIMENTAL
Intervention: Active cervical range of motion (ROM) measurements
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive cervical range of motion (ROM) measurements
Number of subjects: 40
Study: 8122496

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 alpha‐pregnane‐3,20‐dione
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one
Number of subjects: 0
Study: 2545765

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) 100U MRC, im
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT)
Number of subjects: 6
Study: 335791

Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TP) 6 g daily with unilateral ECT
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo with unilateral ECT
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: L-TP treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: L-TP treatment with ECT
Number of subjects: 2
Study: 29324569

Group type: EXPERIMENTAL
Intervention: Abdominal sacrocervicopexy + subtotal hysterectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal sacrospinous fixation + vaginal hysterectomy
Number of subjects: 50
Study: 29231339

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding combined with ginger-partitioned moxibustion (CECGP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 60
Study: 26551272

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of less than 120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of less than 140 mm Hg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361
Study: 23519495

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (TLC)
Number of subjects: 0
Study: 21555684

Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin (3.6 mg subcutaneously every 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 18635155

Group type: EXPERIMENTAL
Intervention: Aroma group (lavender essential oil exposure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no lavender exposure)
Number of subjects: 30
Study: 16822129

Group type: EXPERIMENTAL
Intervention: Grasping and using an object (e.g., drinking from a cup)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finger lifting in association with the object's position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic categorizations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letter identification task
Number of subjects: 0
Study: 14728085

Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 0
Study: 10901185

Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype in patients with nephropathy
Number of subjects: 174

Group type: COMPARATOR
Intervention: GSTM1 null genotype in patients without nephropathy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Comparison of GSTM1 null genotype frequency
Number of subjects: 174
Study: 8791035

Group type: EXPERIMENTAL
Intervention: 10 mg 5-HTP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 mg 5-HTP
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg 5-HTP
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1591831

Group type: EXPERIMENTAL
Intervention: 8 weeks of exercise training
Number of subjects: 17
Study: 6233718

Group type: EXPERIMENTAL
Intervention: Rotational manipulation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Minimal massage and low-level electrostimulation (Control)
Number of subjects: 81
Study: 30121131

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 138
Study: 27725941

Group type: EXPERIMENTAL
Intervention: 6-week physiotherapist-supervised and home-based exercise program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 12
Study: 25607709

Group type: EXPERIMENTAL
Intervention: Sinecatechins 15% ointment BID
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 42
Study: 23121257

Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 50
Study: 20887691

Group type: EXPERIMENTAL
Intervention: Behavioral prevention intervention based on a cognitive model
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Self-reported likelihood to have sex
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Cubic term of the usp assessing three bifurcating variables (planning to have sex, intrinsic rewards from sex, self-efficacy for abstinence)
Number of subjects: 1241
Study: 18558026

Group type: EXPERIMENTAL
Intervention: Culturally influenced educational intervention on healthy eating, physical activity, social support, and goal setting delivered in a group-discussion format for the first 6 months.
Number of subjects: 200
Study: 15717109

Group type: EXPERIMENTAL
Intervention: Patients with myasthenia gravis (MG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with elevated autoantibody concentrations
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 12598482

Group type: EXPERIMENTAL
Intervention: Loaded inspiratory resistance
Number of subjects: 10

Group type: COMPARATOR
Intervention: No inspiratory resistance (control)
Number of subjects: 10